Literature DB >> 10190842

Ethical challenges in critical care medicine: a Chinese perspective.

Y Cong1.   

Abstract

The major ethical challenges for critical care medicine in China include the high cost of patient care in the ICU, the effect of payment mechanisms on access to critical care, the fact that much more money is spent on patients who die than on ones who live, the extent to which an attempt to rescue and save a patient is made, and the great geographical disparity in distribution of critical care. The ethical problems surrounding critical care medicine bear much relation to the culture, public policy and health care system in China. The essay concludes that China should allocate more resources to ordinary medical services rather than to critical care medicine.

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Year:  1998        PMID: 10190842     DOI: 10.1076/jmep.23.6.581.2558

Source DB:  PubMed          Journal:  J Med Philos        ISSN: 0360-5310


  4 in total

1.  Attitudes towards ethical problems in critical care medicine: the Chinese perspective.

Authors:  Li Weng; Gavin M Joynt; Anna Lee; Bin Du; Patricia Leung; Jinming Peng; Charles D Gomersall; Xiaoyun Hu; Hui Y Yap
Journal:  Intensive Care Med       Date:  2011-01-25       Impact factor: 17.440

2.  [Intercultural differences in the treatment of severely injured patients with poor prognosis. Using the example of a 23-year-old Chinese patient].

Authors:  C Schöneberg; T Gasser; W Gao; S Tampier; C Waydhas
Journal:  Unfallchirurg       Date:  2013-01       Impact factor: 1.000

Review 3.  Clinical review: Ethics and end-of-life care for critically ill patients in China.

Authors:  Li Bin Li
Journal:  Crit Care       Date:  2013-12-04       Impact factor: 9.097

4.  The Associations Between the Religious Background, Social Supports, and Do-Not-Resuscitate Orders in Taiwan: An Observational Study.

Authors:  Kuan-Han Lin; Yih-Sharng Chen; Nai-Kuan Chou; Sheng-Jean Huang; Chau-Chung Wu; Yen-Yuan Chen
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.